Back to list

Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: Results from the Filipino cohort of the A1chieve study

Mary Anne Lim-Abrahan, Susan Yu-Gan, Anand B. Jain, Leorino M. Sobrepena and Veronica A. Racho

Diabetes Research and Clinical Practice, pages S35 - S40

Published online Aug-2013

Article view:



To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Filipino patients with type 2 diabetes previously treated with biphasic human insulin 30 (BHI 30). Methods: Safety and effectiveness outcomes were measured in all patients switching from BHI 30 to BIAsp 30 in the Filipino cohort of the 24-week, multinational, prospective, non-interventional A1chieve study.


A total of 111 Filipino patients (mean age ± SD, 57.4±12.8 years; BMI, 25.8±5.6kg/m2) with mean diabetes duration of 9.9±7.1 years switched therapy from BHI 30 to BIAsp 30. The mean pre-study BHI 30 dose was 0.65±0.28 IU/kg and the baseline BIAsp 30 dose was 0.65±0.26 U/kg titrated up to 0.70±0.26 U/kg by Week 24. No serious adverse drug reactions were reported. Overall hypoglycaemia was reduced from 5.62 to 1.98 events/patient-year. Minor and nocturnal hypoglycaemia decreased and no major hypoglycaemia was reported at Week 24. Glucose control improved from baseline to Week 24 (HbA1c, –2.2±2.1% [24±23 mmol/mol]; FPG, –72.0±71.8 mg/dL; PPPG, –145.5±125.4 mg/dL). A total of 24 patients achieved HbA1c levels <7.0% at Week 24 compared to 6 patients reporting this target at baseline. Quality of life was positively impacted at Week 24 (change in visual analogue scores, 15.3±16.9 points).


Switching from BHI 30 to BIAsp 30 improved glycaemic control without increasing the risk of hypoglycaemia.

Keywords: Philippines, Switch therapy, Biphasic insulin aspart 30, Biphasic human insulin 30.

Back to list